Cytokinetics (CYTK)

$65.42 +0.82 (1.27%)
Market Cap 7.55B
Revenue (ttm) 18.47M
Net Income (ttm) -589.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,191.82%
Debt to Equity Ratio -0.38
Volume 2,458,700
Avg Vol 1,989,346
Day's Range N/A - N/A
Shares Out 122.27M
Stochastic %K 85%
Beta 0.55
Analysts Strong Sell
Price Target $86.63

Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It a...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 624 3000
Address:
350 Oyster Point Boulevard, South San Francisco, United States
UsandThem7
UsandThem7 Jan. 7 at 9:07 PM
$CYTK Up on a down day. The tutes are loading.
0 · Reply
felps2
felps2 Jan. 6 at 9:58 PM
$CYTK nice
0 · Reply
timfris
timfris Jan. 3 at 1:58 PM
$CYTK I could use a buyout for JPM. Might as well be this one.
0 · Reply
garygb
garygb Jan. 2 at 8:05 PM
$CYTK looking better.
0 · Reply
UsandThem7
UsandThem7 Jan. 1 at 4:23 AM
$CYTK take it to the limit.🎶
0 · Reply
kFella
kFella Dec. 31 at 7:28 PM
$CYTK might have something to do with the volume spike
0 · Reply
UsandThem7
UsandThem7 Dec. 31 at 6:03 PM
$CYTK someone bought $7 million worth at 12:40 and it wasn’t retail.
1 · Reply
Inarius
Inarius Dec. 31 at 12:08 AM
$CYTK need to wait a year , sales need to come to fruition. Acacia is FAR from priced in. Stay calm and stack CYTK
0 · Reply
buddyopalosam
buddyopalosam Dec. 30 at 3:14 PM
$CYTK mid to low 50's incoming. Might stabilize there waiting for execution results. Gonna be dead money for a little while.
0 · Reply
Inarius
Inarius Dec. 28 at 9:32 PM
$CYTK give me mid 70s and triple digits in a year
0 · Reply
Latest News on CYTK
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:00 PM EST - 2 days ago

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Cytokinetics: Small Label Differences With Big Commercial Stakes

Dec 22, 2025, 5:33 PM EST - 16 days ago

Cytokinetics: Small Label Differences With Big Commercial Stakes

Cytokinetics Wins FDA Nod For Heart Drug Myqorzo

Dec 22, 2025, 11:23 AM EST - 16 days ago

Cytokinetics Wins FDA Nod For Heart Drug Myqorzo

Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript

Dec 22, 2025, 9:47 AM EST - 16 days ago

Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript

US FDA approves Cytokinetics' heart disease drug

Dec 19, 2025, 4:08 PM EST - 19 days ago

US FDA approves Cytokinetics' heart disease drug

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Dec 19, 2025, 4:00 PM EST - 19 days ago

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Dec 17, 2025, 7:30 AM EST - 21 days ago

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Dec 16, 2025, 4:00 PM EST - 22 days ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Dec 12, 2025, 8:42 AM EST - 26 days ago

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

3 Potential Mid-Cap Biotech Buyout Targets In 2026

Dec 3, 2025, 6:22 PM EST - 5 weeks ago

3 Potential Mid-Cap Biotech Buyout Targets In 2026

COGT IBB TVTX XBI

Cytokinetics: A Heavily Mispriced Cardiovascular Platform

Nov 19, 2025, 7:40 AM EST - 7 weeks ago

Cytokinetics: A Heavily Mispriced Cardiovascular Platform

Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

Nov 17, 2025, 8:10 AM EST - 7 weeks ago

Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Nov 12, 2025, 7:28 PM EST - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Nov 10, 2025, 6:16 PM EST - 2 months ago

CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Nov 10, 2025, 7:30 AM EST - 2 months ago

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Nov 7, 2025, 10:01 AM EST - 2 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Cytokinetics, Incorporated (CYTK) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:46 AM EST - 2 months ago

Cytokinetics, Incorporated (CYTK) Q3 2025 Earnings Call Transcript

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 4:00 PM EST - 2 months ago

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

Cytokinetics to Participate in November Investor Conferences

Nov 4, 2025, 4:00 PM EST - 2 months ago

Cytokinetics to Participate in November Investor Conferences

Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Oct 31, 2025, 7:30 AM EDT - 2 months ago

Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments

Oct 28, 2025, 4:32 PM EDT - 2 months ago

Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments

Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market

Oct 28, 2025, 3:08 PM EDT - 2 months ago

Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market

CYTK INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Oct 23, 2025, 1:37 PM EDT - 2 months ago

CYTK INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Cytokinetics to Announce Third Quarter Results on November 5, 2025

Oct 22, 2025, 4:00 PM EDT - 2 months ago

Cytokinetics to Announce Third Quarter Results on November 5, 2025

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

Oct 7, 2025, 7:58 AM EDT - 3 months ago

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025

Sep 29, 2025, 4:21 PM EDT - 3 months ago

Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025

Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025

Sep 29, 2025, 7:30 AM EDT - 3 months ago

Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025

Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately

Sep 25, 2025, 4:32 PM EDT - 3 months ago

Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately

Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program

Sep 24, 2025, 7:30 AM EDT - 3 months ago

Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program

Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Sep 23, 2025, 4:00 PM EDT - 3 months ago

Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Sep 19, 2025, 10:18 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Cytokinetics, Inc. Investigated by the Portnoy Lawfirm

Sep 18, 2025, 4:23 PM EDT - 3 months ago

Cytokinetics, Inc. Investigated by the Portnoy Lawfirm

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Cytokinetics, Incorporated (CYTK)

Sep 18, 2025, 10:30 AM EDT - 3 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Cytokinetics, Incorporated (CYTK)

UsandThem7
UsandThem7 Jan. 7 at 9:07 PM
$CYTK Up on a down day. The tutes are loading.
0 · Reply
felps2
felps2 Jan. 6 at 9:58 PM
$CYTK nice
0 · Reply
timfris
timfris Jan. 3 at 1:58 PM
$CYTK I could use a buyout for JPM. Might as well be this one.
0 · Reply
garygb
garygb Jan. 2 at 8:05 PM
$CYTK looking better.
0 · Reply
UsandThem7
UsandThem7 Jan. 1 at 4:23 AM
$CYTK take it to the limit.🎶
0 · Reply
kFella
kFella Dec. 31 at 7:28 PM
$CYTK might have something to do with the volume spike
0 · Reply
UsandThem7
UsandThem7 Dec. 31 at 6:03 PM
$CYTK someone bought $7 million worth at 12:40 and it wasn’t retail.
1 · Reply
Inarius
Inarius Dec. 31 at 12:08 AM
$CYTK need to wait a year , sales need to come to fruition. Acacia is FAR from priced in. Stay calm and stack CYTK
0 · Reply
buddyopalosam
buddyopalosam Dec. 30 at 3:14 PM
$CYTK mid to low 50's incoming. Might stabilize there waiting for execution results. Gonna be dead money for a little while.
0 · Reply
Inarius
Inarius Dec. 28 at 9:32 PM
$CYTK give me mid 70s and triple digits in a year
0 · Reply
IN0V8
IN0V8 Dec. 26 at 7:01 PM
$CYTK Buying Opportunity Morgan Stanley raises target price to $71 from $65 Truist Securities raises target price to $84 from $70
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 4:00 PM
$CYTK RSI: 44.58, MACD: 0.0207 Vol: 2.41, MA20: 63.74, MA50: 62.80 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
UsandThem7
UsandThem7 Dec. 25 at 1:17 AM
$CYTK the Bernie’s in Manhattan, apparently like the stack. Don’t get your balls, cotton and nut crackers mouth on this one.
0 · Reply
DeathCrossDenny
DeathCrossDenny Dec. 24 at 10:21 AM
$CYTK Current positioning will be tested as timelines compress uncertainty rather than extend speculation. Delays or dilution could materially reshape the risk profile.
0 · Reply
buddyopalosam
buddyopalosam Dec. 23 at 3:41 PM
$CYTK gonna lack volume after today. All the approval pop sellers should be done. But with lack of volume, there are no 10 percent up days. I see this in the 60's and even 50's for a few months before they can prove that they can execute.
1 · Reply
Nopainnogain99
Nopainnogain99 Dec. 23 at 3:22 PM
$CYTK shorts can spin it for awhile but it’s going up $20
0 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 3:16 PM
Morgan Stanley updates rating for Cytokinetics ( $CYTK ) to Overweight, target set at 65 → 71.
0 · Reply
FALCON765
FALCON765 Dec. 23 at 1:59 PM
$CYTK GOT TARGET 136 !
0 · Reply
FALCON765
FALCON765 Dec. 23 at 1:10 PM
$CYTK BIG UPSIDE % ! !
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 5:53 AM
$CYTK RSI: 54.84, MACD: -0.0969 Vol: 2.65, MA20: 64.11, MA50: 62.66 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
biochirp
biochirp Dec. 22 at 9:11 PM
$CYTK rotation of buy the commercial launch investors vs buy the approval investors
0 · Reply
timfris
timfris Dec. 22 at 8:58 PM
$CYTK hopefully some BO rumors before JPM.
0 · Reply